8-K
filed March 16, 2023, 7:59 PM ET
ticker CYPH
CIK 0001509745
other material
confidence high
sentiment neutral
materiality 0.65
BeiGene option for DKN-01 expired; Leap retains global rights, continues clinical collaboration
CYPHERPUNK TECHNOLOGIES INC.
- BeiGene's option to license DKN-01 in Asian territories expired; Leap retains global rights.
- Collaboration continues on Part C of DisTinGuish trial (DKN-01 + tislelizumab + chemo) in first-line gastric cancer; enrollment completion expected late 2023.
- Cash runway extended into mid-2025 following Flame Biosciences acquisition; company seeking new strategic partner for DKN-01.
- Company will also develop Claudin18.2 programs acquired from Flame as part of focus on GI cancers.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
CYPHERPUNK TECHNOLOGIES INC.: Increased ownership threshold required for special voting stock holder to designate a director from 5% to 9.9% (effective 2023-03-16).
- Change
- charter amendment
- Effective
- 2023-03-16
Exact text from the filing
to provide for an increase in the percentage of outstanding shares of Common Stock of the Company that the sole holder of the Company’s Special Voting Stock, together with its affiliates and associates, must hold from 5% to 9.9% in order for such sole holder of the Company’s Special Voting Stock to have the right to designate one (1) individual as a director on the Board of Directors of the Company.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CYPHERPUNK TECHNOLOGIES INC. entered into Letter Agreement with BeiGene, Ltd. (effective 2023-03-16).
- Action
- entry
- Counterparty
- BeiGene, Ltd.
- Effective
- 2023-03-16
Exact text from the filing
On March 16, 2023, Leap Therapeutics, Inc. (the “Company”) and BeiGene, Ltd. (“BeiGene”) entered into a letter agreement (the “Letter Agreement”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
CYPHERPUNK TECHNOLOGIES INC. shareholders approved Approval of Amendment to the Certificate of Designation of the Company's Special Voting Stock at the 2023-03-16 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-03-16
Exact text from the filing
To consider and vote upon a proposal to amend the Certificate of Designation of Special Voting Stock of the Company as set forth in the Certificate of Amendment. 1 0 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.